Menu Search
Equities

Grifols SA

GRFS:NSQ

Grifols SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.59
  • Today's Change0.50 / 5.50%
  • Shares traded1.05m
  • 1 Year change+2.46%
  • Beta0.4975
Data delayed at least 15 minutes, as of Nov 14 2024 16:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform5
Hold5
Sell1
Strong Sell0

Share price forecast in EUR

The 3 analysts offering 12 month price targets for Grifols SA - ADR have a median target of 11.04, with a high estimate of 11.70 and a low estimate of 8.85. The median estimate represents a 21.45% increase from the last price of 9.09.
High28.8%11.70
Med21.4%11.04
Low-2.6%8.85

Earnings history & estimates in EUR

On Nov 07, 2024, Grifols SA - ADR reported 3rd quarter 2024 earnings of 0.16 per share.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate+24.85%
Grifols SA - ADR reported annual 2023 earnings of 0.368 per share on Feb 29, 2024.
Average growth rate-14.77%
More ▼

Revenue history & estimates in EUR

Grifols SA - ADR had 3rd quarter 2024 revenues of 1.79bn. This bettered the 1.74bn consensus of the 3 analysts covering the company. This was 14.82% above the prior year's 3rd quarter results.
Average growth rate+3.27%
Grifols SA - ADR had revenues for the full year 2023 of 6.59bn. This was 8.71% above the prior year's results.
Average growth rate+7.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.